PT - JOURNAL ARTICLE AU - Parker, Anna M. AU - Jackson, Nicole AU - Awasthi, Shevya AU - Kim, Hanna AU - Alwan, Tess AU - Wyllie, Anne L. AU - Baldwin, Alisha B. AU - Brennick, Nicole B. AU - Moehle, Erica A. AU - Giannikopoulos, Petros AU - Kogut, Katherine AU - Holland, Nina AU - Mora-Wyrobek, Ana AU - Eskenazi, Brenda AU - Riley, Lee W. AU - Lewnard, Joseph A. TI - Association of upper respiratory <em>Streptococcus pneumoniae</em> colonization with SARS-CoV-2 infection among adults AID - 10.1101/2022.10.04.22280709 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.04.22280709 4099 - http://medrxiv.org/content/early/2022/10/05/2022.10.04.22280709.short 4100 - http://medrxiv.org/content/early/2022/10/05/2022.10.04.22280709.full AB - Background Streptococcus pneumoniae interacts with numerous viral respiratory pathogens in the upper airway. It is unclear whether similar interactions occur with SARS-CoV-2.Methods We collected saliva specimens from working-age adults receiving SARS-CoV-2 molecular testing at outpatient clinics and via mobile community-outreach testing between July and November 2020 in Monterey County, California. Following bacterial culture enrichment, we tested for pneumococci by quantitative polymerase chain reaction (qPCR) targeting the lytA and piaB genes, and measured associations with SARS-CoV-2 infection via conditional logistic regression.Results Analyses included 1,278 participants, with 564 enrolled in clinics and 714 enrolled through outreach-based testing. Prevalence of pneumococcal carriage was 9.2% (117/1,278) among all participants (11.2% [63/564] clinic-based testing; 7.6% [54/714] outreach testing). Prevalence of SARS-CoV-2 infection was 27.4% (32/117) among pneumococcal carriers and 9.6% (112/1,161) among non-carriers (adjusted odds ratio [aOR]: 2.73; 95% confidence interval: 1.58-4.69). Associations between SARS-CoV-2 infection and pneumococcal carriage were enhanced in the clinic-based sample (aOR=4.01 [2.08-7.75]) and among symptomatic participants (aOR=3.38 [1.35-8.40]), when compared to findings within the outreach-based sample and among asymptomatic participants. Adjusted odds of SARS-CoV-2 co-infection increased 1.24 (1.00-1.55)-fold for each 1-unit decrease in piaB qPCR CT value among pneumococcal carriers. Last, pneumococcal carriage modified the association of SARS-CoV-2 infection with recent exposure to a suspected COVID-19 case (aOR=7.64 [1.91-30.7] and 3.29 [1.94-5.59]) among pneumococcal carriers and non-carriers, respectively).Conclusions Associations of pneumococcal carriage detection and density with SARS-CoV-2 suggest a synergistic relationship in the upper airway. Longitudinal studies are needed to determine interaction mechanisms between pneumococci and SARS-CoV-2.Key pointsIn an adult ambulatory and community sample, SARS-CoV-2 infection was more prevalent among pneumococcal carriers than non-carriers.Associations between pneumococcal carriage and SARS-CoV-2 infection were strongest among adults reporting acute symptoms and receiving SARS-CoV-2 testing in a clinical setting.Competing Interest StatementJAL discloses receipt of grant funding and consulting honoraria from Pfizer, Inc.; grant funding and consulting honoraria from Merck, Sharp &amp; Dohme; and consulting honoraria from VaxCyte, Inc.Funding StatementThe study was supported by the Innovative Genomics Institute at the University of California, Berkeley; Pfizer, Inc. (grant 61775823 to JAL); and the National Institutes of Health (grants R24ES028529 and R24ESD30888 to NH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Committee for Protection of Human Subjects of the University of California, Berkeley.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProduced in the present study are available upon reasonable request to the authors, for investigators who will collaborate with the investigators in secondary analyses under the oversight of applicable UC Berkeley ethics committees.